Keywords: reopro, reduces, mortality, capture, study, centocor, abciximab
ReoPro Reduces Mortality In CAPTURE Study
Article | 15 April 1996
Centocor's ReoPro (abciximab) reduced mortality and myocardial infarction by 50% in patients with unstable angina undergoing coronary angioplasty, according to a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
